Kymriah Poised For Expansion In Follicular Lymphoma, Leveling The Field With Yescarta
Novartis will present data from the pivotal Phase II ELARA trial of the CAR-T therapy in relapsed/refractory follicular lymphoma at ASCO.
You may also be interested in...
Keeping Track: Parsaclisib, Kymriah Applications Target Non-Hodgkin Lymphomas; AbbVie Gets New Use For Old Ophthalmic
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Gilead announced positive topline results from the ZUMA-7 trial of Yescarta in second-line large B-cell lymphoma, where the CAR-T would eventually compete with BMS’s Breyanzi and Novartis’ Kymriah.
Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.